Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.83 Insider Own0.50% Shs Outstand78.50M Perf Week-2.61%
Market Cap6.55B Forward P/E- EPS next Y-5.96 Insider Trans-0.58% Shs Float75.12M Perf Month-8.30%
Income-600.50M PEG- EPS next Q-1.87 Inst Own90.80% Short Float8.94% Perf Quarter-43.46%
Sales495.10M P/S13.23 EPS this Y-77.80% Inst Trans-1.91% Short Ratio3.17 Perf Half Y-39.90%
Book/sh11.36 P/B7.46 EPS next Y11.90% ROA-23.00% Target Price130.05 Perf Year-29.38%
Cash/sh23.50 P/C3.61 EPS next 5Y- ROE-61.60% 52W Range77.01 - 181.83 Perf YTD-50.27%
Dividend- P/FCF138.22 EPS past 5Y-23.40% ROI-47.10% 52W High-53.37% Beta1.75
Dividend %- Quick Ratio5.60 Sales past 5Y108.10% Gross Margin88.60% 52W Low10.10% ATR4.71
Employees743 Current Ratio6.10 Sales Q/Q45.40% Oper. Margin- RSI (14)36.43 Volatility6.51% 5.23%
OptionableYes Debt/Eq0.79 EPS Q/Q-47.00% Profit Margin- Rel Volume0.84 Prev Close82.16
ShortableYes LT Debt/Eq0.79 EarningsMar 01 AMC Payout- Avg Volume2.12M Price84.79
Recom2.20 SMA20-4.62% SMA50-22.73% SMA200-39.46% Volume1,776,546 Change3.20%
Jan-12-21Downgrade Citigroup Buy → Neutral $215 → $108
Jan-11-21Downgrade UBS Buy → Neutral
Jan-08-21Downgrade Raymond James Outperform → Mkt Perform
Jan-08-21Downgrade Morgan Stanley Overweight → Equal-Weight $95
Jan-08-21Downgrade JP Morgan Overweight → Underweight $96
Nov-11-20Initiated Berenberg Hold
Oct-28-20Initiated UBS Buy $212
Aug-25-20Initiated Raymond James Outperform $200
Aug-20-20Downgrade Credit Suisse Outperform → Neutral $185 → $167
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Mar-02-21 10:02AM  
08:57AM  
02:01AM  
Mar-01-21 05:55PM  
04:28PM  
04:05PM  
02:30PM  
Feb-26-21 07:12PM  
10:16AM  
Feb-25-21 03:48PM  
02:10PM  
Feb-24-21 04:30PM  
Feb-22-21 08:30AM  
05:48AM  
Feb-16-21 09:11AM  
Feb-15-21 09:39PM  
Feb-13-21 03:30PM  
Feb-11-21 12:37PM  
Feb-08-21 07:10PM  
11:11AM  
Feb-06-21 11:18PM  
Feb-04-21 07:01PM  
04:30PM  
Feb-03-21 11:15AM  
Feb-01-21 05:16PM  
Jan-29-21 08:30PM  
Jan-22-21 07:00AM  
Jan-21-21 10:35AM  
Jan-15-21 01:20PM  
Jan-14-21 12:28PM  
10:26AM  
Jan-13-21 01:00PM  
08:30AM  
Jan-12-21 01:30PM  
10:17AM  
08:57AM  
06:00AM  
Jan-11-21 08:01PM  
03:11PM  
02:45PM  
12:00PM  
08:11AM  
Jan-10-21 01:00PM  
07:56AM  
Jan-09-21 07:15PM  
01:15PM  
Jan-08-21 07:23PM  
06:48PM  
05:16PM  
04:30PM  
01:35PM  
01:25PM  
11:57AM  
11:44AM  
11:38AM  
10:15AM  
09:39AM  
09:36AM  
09:08AM  
08:30AM  
Jan-07-21 05:13PM  
05:11PM  
04:05PM  
Jan-06-21 04:15PM  
Jan-05-21 06:00AM  
Jan-04-21 10:32AM  
Dec-31-20 06:30PM  
Dec-24-20 04:41AM  
Dec-22-20 12:56PM  
Dec-20-20 03:14PM  
Dec-18-20 02:00PM  
Dec-14-20 08:30AM  
Dec-09-20 10:42AM  
Dec-08-20 10:07AM  
Dec-07-20 01:57PM  
08:55AM  
Dec-05-20 11:32AM  
Dec-04-20 04:05PM  
Nov-30-20 06:05PM  
Nov-25-20 08:30AM  
Nov-20-20 08:30AM  
Nov-09-20 09:30AM  
Nov-06-20 02:27PM  
12:01PM  
10:51AM  
Nov-05-20 04:59PM  
04:05PM  
04:02PM  
02:45PM  
Nov-02-20 04:30PM  
Oct-30-20 07:16PM  
Oct-29-20 02:25PM  
12:35PM  
08:36AM  
Oct-23-20 12:56PM  
Oct-22-20 07:30AM  
Oct-01-20 04:43PM  
02:56PM  
Sep-30-20 06:15PM  
Sep-28-20 05:06PM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bratica JosephPrincipal Financial OfficerDec 11Option Exercise71.451,11579,6679,255Dec 14 08:00 PM
Bratica JosephPrincipal Financial OfficerDec 11Sale165.001,115183,9758,140Dec 14 08:00 PM
GRAY MARY ANNDirectorDec 10Option Exercise0.0096705,710Dec 10 08:24 PM
Bratica JosephPrincipal Financial OfficerDec 08Option Exercise29.601,12533,3009,265Dec 10 08:23 PM
Bratica JosephPrincipal Financial OfficerDec 08Sale160.001,125180,0008,140Dec 10 08:23 PM
Wigzell Hans Lennart RudolfDirectorAug 10Option Exercise34.9210,000349,20023,792Aug 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 10Sale159.0010,0001,590,04413,792Aug 11 08:00 PM
Barry RichardDirectorAug 07Sale158.5030,0004,754,9723,129,140Aug 07 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Option Exercise29.601,12533,3008,957Aug 05 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Sale155.001,125174,3757,832Aug 05 08:00 PM
Mahatme SandeshEVP, CFO & CBOJul 08Option Exercise19.693,80674,94120,260Jul 09 08:00 PM
Howton David TEVP, General CounselJun 22Option Exercise25.76105,1222,708,440136,993Jun 22 09:17 PM
Howton David TEVP, General CounselJun 22Sale170.88105,12217,962,83131,871Jun 22 09:17 PM
Wigzell Hans Lennart RudolfDirectorMay 20Option Exercise10.085,00050,40018,792May 22 08:00 PM
Wigzell Hans Lennart RudolfDirectorMay 20Sale150.645,000753,21013,792May 22 08:00 PM
Barry RichardDirectorMay 15Sale141.2630,0004,237,9463,159,140May 15 09:02 PM